| Naslov: | Hypopituitarism and cardiovascular risk |
|---|
| Avtorji: | ID Kraljević, Ivana (Avtor)
ID Solak, Mirsala (Avtor)
ID Mandić, Ante (Avtor)
ID Mlekuš, Katarina (Avtor)
ID Raičević, Maja (Avtor)
ID Divanović Slato, Anida (Avtor)
ID Kovačević, Zlata (Avtor)
ID Muzurović, Emir (Avtor) |
|---|
| Datoteke: |  PDF - Predstavitvena datoteka, prenos (626,41 KB)
MD5: C6F76A65C06F4162AD0BF7F54A930882
 URL - Izvorni URL, za dostop obiščite https://journals.sagepub.com/doi/10.1177/10742484251332398
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.02 - Pregledni znanstveni članek |
|---|
| Organizacija: |  UKC LJ - Univerzitetni klinični center Ljubljana
|
|---|
| Povzetek: | Hypopituitarism, resulting from a partial or complete deficiency of anterior or posterior pituitary hormones, is associated with increased cardiovascular (CV) morbidity and mortality. This heterogeneous endocrinological disorder may arise from various etiologies, including genetic mutations, pituitary tumors, traumatic brain injury, and autoimmune diseases. Hypopituitarism often results in multiple endocrine deficits that contribute to metabolic dysregulation characterized by insulin resistance, dyslipidemia, and increased visceral adiposity, all known risk factors for CV disease (CVD). Additionally, the presence of chronic inflammation and endothelial dysfunction further increases the risk of CVD in these patients. While standard hormone replacement therapy (HRT) is crucial for restoring hormonal balance, it can sometimes have adverse metabolic effects that can exacerbate atherosclerosis and CVD. Emerging evidence suggests that optimizing HRT regimens and addressing specific hormone deficiencies, such as growth hormone and cortisol, may reduce these risks and improve CV outcomes. This review comprehensively analyzes the etiology, pathophysiological mechanisms underlying CV risk in anterior pituitary dysfunction, and treatment strategies to mitigate CV morbidity and mortality in patients with hypopituitarism. |
|---|
| Ključne besede: | hypopituitarism, cardiovascular risk, cardiovascular disease, GH deficiency, hormone replacement therapy |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Leto izida: | 2025 |
|---|
| Št. strani: | str. 1-22 |
|---|
| Številčenje: | Vol. 30 |
|---|
| PID: | 20.500.12556/DiRROS-29267  |
|---|
| UDK: | 616.1 |
|---|
| ISSN pri članku: | 1940-4034 |
|---|
| DOI: | 10.1177/1074248425133239 |
|---|
| COBISS.SI-ID: | 275553027 |
|---|
| Opomba: |
Nasl. z nasl. zaslona;
Opis vira z dne 17. 4. 2026;
|
|---|
| Datum objave v DiRROS: | 05.05.2026 |
|---|
| Število ogledov: | 40 |
|---|
| Število prenosov: | 22 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
